{"id":16649,"date":"2021-01-05T01:25:22","date_gmt":"2021-01-04T22:25:22","guid":{"rendered":"https:\/\/www.klimikdergisi.org\/\/2021\/01\/05\/kronik-hepatit-c-hastalarinin-bes-yillik-tedavi-sonuclarinin-degerlendirilmesi\/"},"modified":"2021-01-05T01:25:22","modified_gmt":"2021-01-04T22:25:22","slug":"kronik-hepatit-c-hastalarinin-bes-yillik-tedavi-sonuclarinin-degerlendirilmesi","status":"publish","type":"post","link":"https:\/\/www.klimikdergisi.org\/tr\/2021\/01\/05\/kronik-hepatit-c-hastalarinin-bes-yillik-tedavi-sonuclarinin-degerlendirilmesi\/","title":{"rendered":"Kronik Hepatit C Hastalar\u0131n\u0131n Be\u015f Y\u0131ll\u0131k Tedavi Sonu\u00e7lar\u0131n\u0131n De\u011ferlendirilmesi"},"content":{"rendered":"<h1>\u00d6zet<\/h1>\n<p> <strong>Ama\u00e7<\/strong>: Bu \u00e7al\u0131\u015fmada hepatit C virusu (HCV) genotip 1 ile infekte kronik hepatit C (KHC) hastalar\u0131ndaki son be\u015f y\u0131ll\u0131k tedavi sonu\u00e7lar\u0131m\u0131z\u0131n retrospektif olarak de\u011ferlendirilmesi ama\u00e7lanm\u0131\u015ft\u0131r.<\/p>\n<p> <strong>Y\u00f6ntemler<\/strong>: 2004-2009 y\u0131llar\u0131 aras\u0131nda KHC tan\u0131s\u0131 al\u0131p tedavi g\u00f6ren \u00a0245 hastan\u0131n tedavi sonu\u00e7lar\u0131 de\u011ferlendirildi. Yan etki ya da di\u011fer nedenlerle hem pegile interferon (PEG IFN) hem de ribavirin dozlar\u0131n\u0131 arka arkaya \u00fc\u00e7 haftadan fazla aksatmam\u0131\u015f olan, tedavi s\u00fcresini tamamlam\u0131\u015f, takip randevular\u0131na d\u00fczenli olarak gelmi\u015f, verileri tam olup \u00e7al\u0131\u015fmaya dahil edilebilen naif hasta say\u0131s\u0131 98\u2019di. Yap\u0131lan karaci\u011fer biyopsisinde kronik karaci\u011fer hastal\u0131\u011f\u0131 saptanm\u0131\u015f ve HCV RNA-pozitif olan hastalara KHC tan\u0131s\u0131 konularak PEG IFN ve ribavirin tedavisi ba\u015fland\u0131. Tedavi sonu yan\u0131t (TSY) al\u0131n\u0131p, ancak kal\u0131c\u0131 viral yan\u0131t (KVY) elde edilemeyen ve n\u00fcks olarak kabul edilen KHC hastalar\u0131na, verilen birinci k\u00fcrde PEG IFN-\u03b1 2a ald\u0131ysa 2b, 2b ald\u0131ysa 2a verilerek ribavirinle birlikte ikinci k\u00fcr yap\u0131ld\u0131.<\/p>\n<p> <strong>Bulgular<\/strong>: 98 hastadan 58\u2019ine PEG IFN-\u03b1 2a (Grup 1), 31\u2019ine PEG IFN-\u03b1 2b (Grup 2) ve 9\u2019una ise yan etki nedeniyle PEG IFN\u2019lerden biriyle ba\u015flan\u0131p, di\u011feriyle devam edilmi\u015fti (Grup 3). Erken virolojik yan\u0131t (EVY) a\u00e7\u0131s\u0131ndan Grup 1 ile 2 aras\u0131ndaki fark istatistiksel olarak anlaml\u0131 de\u011filken (p=0.12, p=0.08, p=0.04), KVY a\u00e7\u0131s\u0131ndan anlaml\u0131yd\u0131 (p=0.007, p=0.85, p&lt;0.001). Grup 3 ile di\u011fer iki grup aras\u0131nda ise hem EVY hem de KVY a\u00e7\u0131s\u0131ndan iyile\u015fmeme y\u00f6n\u00fcnde istatistiksel olarak anlaml\u0131 bir fark s\u00f6z konusuydu. \u0130kinci k\u00fcr sonras\u0131nda farkl\u0131 IFN alan gruplar aras\u0131nda tedavi yan\u0131tlar\u0131 a\u00e7\u0131s\u0131ndan istatistiksel olarak anlaml\u0131 bir fark saptanmad\u0131. Genel olarak hangi IFN kullan\u0131ld\u0131\u011f\u0131na bak\u0131lmaks\u0131z\u0131n tedavi ba\u015flanan toplam 98 hastan\u0131n sonu\u00e7lar\u0131 de\u011ferlendirildi\u011finde, KVY oran\u0131 birinci k\u00fcrle %48 (47\/98), ikinci k\u00fcrle ise %58 (11\/19) olarak \u00a0saptand\u0131.<\/p>\n<p> <strong>Sonu\u00e7lar<\/strong>: \u0130lk k\u00fcr sonras\u0131nda KVY elde edilemeyen KHC hastalar\u0131n\u0131n yar\u0131dan fazlas\u0131nda ikinci k\u00fcrden sonra KVY elde edilebilmektedir. Bu nedenle TSY elde edilen hastalarda tedavi s\u00fcresinin 48 haftadan 72 haftaya uzat\u0131lmas\u0131 d\u00fc\u015f\u00fcn\u00fclebilir.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00d6zet Ama\u00e7: Bu \u00e7al\u0131\u015fmada hepatit C virusu (HCV) genotip 1 ile infekte kronik hepatit C (KHC) hastalar\u0131ndaki son be\u015f y\u0131ll\u0131k tedavi sonu\u00e7lar\u0131m\u0131z\u0131n retrospektif olarak de\u011ferlendirilmesi ama\u00e7lanm\u0131\u015ft\u0131r. Y\u00f6ntemler: 2004-2009 y\u0131llar\u0131 aras\u0131nda KHC tan\u0131s\u0131 al\u0131p tedavi g\u00f6ren \u00a0245 hastan\u0131n tedavi sonu\u00e7lar\u0131 de\u011ferlendirildi. Yan etki ya da di\u011fer nedenlerle hem pegile interferon (PEG IFN) hem de ribavirin dozlar\u0131n\u0131 [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5129],"tags":[3985,3026,3983,3874],"class_list":["post-16649","post","type-post","status-publish","format-standard","hentry","category-ozgun-arastirma","tag-hepatit-c-virusu-genotip-1","tag-kronik-hepatit-c","tag-pegile-interferon","tag-ribavirin"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/posts\/16649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/comments?post=16649"}],"version-history":[{"count":0,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/posts\/16649\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/media?parent=16649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/categories?post=16649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/tr\/wp-json\/wp\/v2\/tags?post=16649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}